Loading...
XCNQINNO
Market cap36mUSD
Dec 20, Last price  
0.19CAD
1D
-5.13%
1Q
-22.92%
IPO
-26.00%
Name

Innocan Pharma Corp

Chart & Performance

D1W1MN
XCNQ:INNO chart
P/E
P/S
2.70
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
12.30%
Rev. gr., 5y
%
Revenues
14m
+433.69%
008,000196,0002,559,00013,657,000
Net income
-5m
L+20.85%
-1,192,000-3,669,000-15,181,000-10,060,000-3,889,000-4,700,000
CFO
-4m
L-35.65%
-909,000-2,715,000-3,687,000-6,629,000-6,067,000-3,904,000

Profile

InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
IPO date
Sep 24, 2019
Employees
Domiciled in
IL
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
13,657
433.69%
2,559
1,205.61%
196
2,350.00%
Cost of revenue
17,460
8,825
7,676
Unusual Expense (Income)
NOPBT
(3,803)
(6,266)
(7,480)
NOPBT Margin
Operating Taxes
214
1,000
(31)
Tax Rate
NOPAT
(4,017)
(6,267)
(7,449)
Net income
(4,700)
20.85%
(3,889)
-61.34%
(10,060)
-33.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,914
BB yield
-2.18%
Debt
Debt current
22
14
1,000
Long-term debt
44
54
1,000
Deferred revenue
Other long-term liabilities
1
Net debt
(3,819)
(4,879)
(11,046)
Cash flow
Cash from operating activities
(3,904)
(6,067)
(6,629)
CAPEX
(46)
(26)
(41)
Cash from investing activities
(84)
(31)
(48)
Cash from financing activities
2,917
125
15,303
FCF
(3,239)
(7,525)
(11,072)
Balance
Cash
3,885
4,947
11,048
Long term investments
Excess cash
3,202
4,819
11,038
Stockholders' equity
(32,791)
(28,543)
(24,654)
Invested Capital
37,210
34,802
33,666
ROIC
ROCE
EV
Common stock shares outstanding
257,004
248,953
224,542
Price
0.31
44.19%
0.22
-73.13%
0.80
138.81%
Market cap
79,671
48.85%
53,525
-70.20%
179,633
230.96%
EV
76,135
48,477
168,543
EBITDA
(3,770)
(6,231)
(7,437)
EV/EBITDA
Interest
2
13
Interest/NOPBT